Known variant DPYD alleles do not explain DPD deficiency in cancer patients.

Abstract excerpt

Dihydropyrimidine dehydrogenase (DPD) degrades over 80% of administered 5-fluorouracil (5FU), thereby regulating the efficacy of this commonly used anticancer agent. DPD activity is highly variable (8-21-fold) and individuals with reduced activity have a high risk of 5FU toxicity. DPYD encodes DPD protein and 13 different mutations have been reported in DPD-deficient subjects. However, the contribution of these...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antimetabolites, Antineoplastic
• Share to Cohort Studies
• Share to Dihydrouracil Dehydrogenase (NADP)